Hypertriglyceridemia malady

Wikipedia: Hypertriglyceridemia denotes high (hyper-) blood levels (-emia) of triglycerides, the most abundant...⁴⁴ more...

MalaCards: Hypertriglyceridemia is related to familial hypertriglyceridemia and lipoprotein lipase deficiency. An important gene associated with Hypertriglyceridemia is APOA5 (apolipoprotein A-V), and among its related pathways are Statin Pathway, Pharmacodynamics and Fat digestion and absorption. The compounds gemfibrozil and bezafibrate have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and lung, and related mouse phenotypes are endocrine/exocrine gland and respiratory system.

OMIM: 145750

hypertriglyceridemia 7 33 32

Diseases related to hypertriglyceridemia by text searches and GeneDecks gene sharing:

(show top 50)    (show all 739)

id	Related Disease	Score	Top Affiliating Genes
1	familial hypertriglyceridemia	34.3	LPL, LMF1, LIPI, USF1, APOA1, APOA2
2	lipoprotein lipase deficiency	33.2	LPA, LPL, LCAT, CETP, INS, APOA1
3	obesity	32.7	ENPP1, GHRL, ADRB2, ADRB3
4	familial combined hyperlipidemia	32.0	APOA1, APOB, APOE, HMGCR
5	familial lipoprotein lipase deficiency	31.3	LPL, APOC2, GPIHBP1
6	atherosclerosis	30.8	SELE, LCAT, CETP, ATHS, ANGPTL3
7	familial hypercholesterolemia	30.5	COG2, LPA, LPL, LIPC, LDLR, LCAT
8	alcoholism	30.1	GSR, GPT, GHRL, HMGCR, ABCB7, TTF2
9	hepatitis	30.0	RBP4, SELP, GSR, FAS, GPT, IFNA1
10	glucose intolerance	29.9	MTTP, APOA4, APOB, GHRL, CYP7A1, PNLIP
11	hypoalphalipoproteinemia	29.7	LPA, LPL, LIPC, LDLR, LCAT, CETP
12	hyperalphalipoproteinemia	29.0	LPL, LIPC, LDLR, LCAT, CETP, APOA1
13	familial hyperlipidemia	28.5	COG2, LPA, LPL, LIPC, USF1, LDLR
14	acquired immunodeficiency syndrome	27.7	LRP1, CETP, MLXIPL, GSR, F9, PPIG
15	immunodeficiency	26.3	ITGB2, INS, INSR, IL18, IL6, FAS
16	hyperlipidemia	26.0	LRP1, COG2, RBP4, SELP, SERPINE1, VLDLR
17	retinol binding protein	25.9	RBP4, NAMPT, LPA, LIPC, LEP, IRS1
18	lipodystrophy	24.9	LRP1, RBP4, SERPINE1, BSCL2, NAMPT, LPA
19	type 2 diabetes mellitus	24.3	COG2, GCKR, RBP4, SELE, SELP, SERPINE1
20	hemochromatosis	24.0	INS, GSTP1, IL6, APOE, GPT, ALB
21	hypercholesterolemia	23.7	LRP1, COG2, RBP4, SELE, SELP, SERPINE1
22	insulin resistance	22.7	LRP1, COG2, GCKR, RBP4, SELE, SELP
23	acute pancreatitis	22.3	SELE, SELP, NAMPT, LPL, LEP, LCAT
24	hypoglycemia	22.2	GCKR, LPL, LEP, INS, INSR, IL1B
25	uremia	22.1	SERPINE1, LPA, LPL, VCAM1, LIPC, LEP
26	hyperglycemia	21.9	COG2, GCKR, SELE, SELP, SERPINE1, NAMPT
27	coronary heart disease	21.0	LRP1, COG2, GCKR, SELE, SELP, SERPINE1
28	pancreatitis	20.2	LRP1, GCKR, RBP4, SELE, SELP, SERPINE1
29	cholesterol	20.2	ZNF259, LRP1, COG2, BUD13, GCKR, RBP4
30	lymphoblastic leukemia	20.1	COG2, SELP, SERPINE1, LPL, USF1, LEP
31	acute lymphoblastic leukemia	20.1	COG2, SELP, SERPINE1, LPL, USF1, LEP
32	diabetes mellitus	19.5	COG2, GCKR, RBP4, SELE, SELP, SERPINE1
33	neuropathy	19.4	SELE, SERPINE1, BSCL2, LMNA, BCHE, LEP
34	blindness	18.8	COG2, RBP4, SELE, SELP, SERPINE1, LPL
35	hypertension	18.3	LRP1, COG2, RBP4, SELE, SELP, SERPINE1
36	peritonitis	18.0	LRP1, COG2, RBP4, SELE, SELP, SERPINE1
37	anemia	18.0	SELE, SELP, NAMPT, LPIN2, LPL, VCAM1
38	melanoma	16.7	LRP1, SELE, SELP, SERPINE1, LPL, LPXN
39	nephropathy	15.8	LRP1, COG2, RBP4, SELE, SELP, SERPINE1
40	leukemia	15.6	LRP1, COG2, RBP4, SELE, SELP, SERPINE1
41	fibrosis	15.2	LRP1, RBP4, SELE, SELP, SERPINE1, LPA
42	hyperlipidemia type 3	14.4	COG2, LPA, LPL, LIPC, LDLR, CETP
43	cetp deficiency	14.3	LPL, LIPC, LDLR, LCAT, CETP, APOA1
44	abetalipoproteinemia	14.3	LPA, LPL, LEP, LCAT, MTTP, CETP
45	xanthomatosis	14.3	LPA, LPL, LDLR, INS, APOA1, APOB
46	hereditary diffuse leukoencephalopathy with spheroids	14.3	LPA, LCAT, CETP, APOA1, APOA2, APOB
47	hepatic lipase deficiency	14.2	LPL, LIPC, LCAT, CES1, APOA1, APOE
48	combined hyperlipemia	14.2	LPL, LIPC, INS, APOA1, APOB
49	defective apolipoprotein b-100	14.2	LDLR, LCAT, APOB, APOE, HMGCR
50	cherubism	14.2	LPL, LDLR, LCAT, CETP, APOB

Clinical features from OMIM: 145750

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to hypertriglyceridemia:

²²

MGI Mouse Phenotypes related to hypertriglyceridemia:

²⁵ (show all 24)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland phenotype	MP:0005379	10.6	ADRB3, LTA, CAV1, LDLR, GGT1
2	respiratory system phenotype	MP:0005388	10.3	SMPD1, APOE, INSR, INPPL1, LMF1, LPL
3	hematopoietic system phenotype	MP:0005397	10.1	BSCL2, UNC13D, GP1BA, TRIB2, TNFSF14, ACSL3
4	other phenotype	MP:0005395	9.8	ABCB7, COL18A1, NOS3, CAV1, ENPP1, APOE
5	pigmentation phenotype	MP:0001186	9.5	FAS, LMNA, BMP7, LIPH, VLDLR, LEP
6	nervous system phenotype	MP:0003631	9.4	SELP, VLDLR, LMNA, BMP7, LDLR, USF1
7	renal/urinary system phenotype	MP:0005367	9.3	CAV1, NOS3, COL18A1, ABCA1, G6PC, FABP2
8	integument phenotype	MP:0010771	9.2	GSTP1, LDLR, SCD, LIPH, LIPI, LMF1
9	liver/biliary system phenotype	MP:0005370	9.0	PPARD, SREBF1, CYP7A1, GK, CAPN10, ANGPTL3
10	reproductive system phenotype	MP:0005389	8.7	IL6, BAZ1B, LEP, BCHE, LIPC, BMP7
11	digestive/alimentary phenotype	MP:0005381	8.4	SLC10A2, PLAT, NOS3, EDN1, ABCA1, HFE
12	skeleton phenotype	MP:0005390	8.3	TFAP2A, UNC13D, INS, C3, AGPAT2, PLAT
13	immune system phenotype	MP:0005387	7.8	BSCL2, LRP1, SELP, LMNA, UNC13D, LDLR
14	muscle phenotype	MP:0005369	7.3	LDLR, PLAT, PLIN1, NOS3, EDN1, ABCA1
15	vision/eye phenotype	MP:0005391	7.3	LEP, LDLR, LCAT, ITGB2, INS, BMP7
16	adipose tissue phenotype	MP:0005375	7.2	INS, IRS1, MLXIPL, FOXC2, LDLR, LEP
17	normal phenotype	MP:0002873	7.2	ITGAX, LDLR, USF1, BMP7, ALB, SELE
18	growth/size phenotype	MP:0005378	6.6	SELP, SERPINE1, VLDLR, BSCL2, LPL, VCAM1
19	tumorigenesis	MP:0002006	6.5	CAT, ICAM1, FAS, IL6, IL1B, GSTP1
20	behavior/neurological phenotype	MP:0005386	6.0	ENPP1, CAV1, FAS, INS, LRP1, GK
21	cellular phenotype	MP:0005384	5.8	CAV1, SELP, IRS1, INS, INSR, IL18
22	mortality/aging	MP:0010768	5.7	PLAT, SLC25A13, C3, GGT1, SLC2A4, PRF1
23	cardiovascular system phenotype	MP:0005385	4.8	INSR, ICAM1, CAPN10, CAV1, TNF, PPARG
24	homeostasis/metabolism phenotype	MP:0005376	4.7	SMPD1, AGPAT2, PRF1, PON1, SLC2A4, SLC10A2

Articles related to hypertriglyceridemia:

(show top 50)    (show all 291)

id	Title	Authors	Year	Affiliating Genes
1	Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. (19820022)	CefalA^ A.B.... Averna M.R.	2009	LMF1
2	Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan. (19187029)	Chang S.Y.... Chang S.C.	2009	APOA5
3	A polygenic basis for four classical Fredrickson hype rlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. (19656773)	Hegele R.A.... Wang J.	2009	LPL, SELP, LDLR
4	APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. (18601597)	Hubacek J.A.... Talmud P.J.	2008	APOA5
5	Polygenic determinants of severe hypertriglyceridemia. (18596051)	Wang J.... Hegele R.A.	2008	LPL, APOE, GALNT2
6	Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. (18635818)	Dorfmeister B.... Talmud P.J.	2008	LPL, LRP1, LDLR
7	Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. (18242616)	Rosenson R.S.... Rademaker A.W.	2008	IL1B
8	Characterization of hypertriglyceridemia and response to treatment with insulin in llamas and alpacas: 31 cases (1995-2005). (18447783)	Waitt L.H.... Cebra C.K.	2008	INS
9	The relationship between apolipoprotein E genotype and hypertriglyceridemia-associated recurrent acute pancreatitis (19094657)	Wen T.... Nie S.	2008	APOE
10	The -1131T>C Polymorphism in the Apolipoprotein A5 Gene is Related to Hypertriglyceridemia in Taiwanese Aborigines. (18424353)	Huang M.C.... Chiang H.C.	2008	APOA5
11	Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. (17457016)	Oki K.... Yamane K.	2007	PPARA, NAMPT, ADIPOQ
12	Effect of rosuvastatin 5-20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. (17223112)	Saito Y.... Fox J.C.	2007	GPT
13	Apolipoprotein E and lipoprotein lipase gene polymorphisms interaction on the atherogenic combined expression of hypertriglyceridemia and hyperapobetalipoproteinemia phenotypes. (17848837)	Perron P.... Gaudet D.	2007	LPL, APOE
14	Analysis of ATP binding cassette A1 gene R219K polymorphism in patients with endogenous hypertriglyceridemia in Chinese population (17407076)	Wu Y.... Liu B.W.	2007	ABCA1
15	Augmentation of Ca2+-induced microsomal triglyceride transfer protein activity by glucose supply enhances hypertriglyceridemia in vivo. (16651714)	Cho H.J.... Park H.J.	2006	MTTP
16	Generation of a recombinant apolipoprotein E variant with improved biological functions: hydrophobic residues (LEU-261, TRP-264, PHE-265, LEU-268, VAL-269) of apoE can account for the apoE-induced hypertriglyceridemia. (15576362)	Kypreos K.E.... Zannis V.I.	2005	LPL, APOE
17	Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice. (15301543)	Chroni A.... Zannis V.I.	2004	LPL, APOA1
18	Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. (15145986)	Miao B.... Mukherjee R.	2004	FAS, ABCA1
19	Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia. (12929621)	Empen K.... Parhofer K.G.	2003	SELE
20	Effects of simvastatin, an HMG-CoA reductase inhibito r, in patients with hypertriglyceridemia. (12539808)	Isaacsohn J.... Mitchel Y.B.	2003	HMGCR
21	Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. (12818412)	Lee S.J.... Sacks F.M.	2003	APOC3
22	Mutations in the lipoprotein lipase gene as a cause of hypertriglyceridemia and pancreatitis in Taiwan. (12883259)	Jap T.S.... Cheng H.M.	2003	LPL
23	Hypertriglyceridemia associated with amino acid variation Asn985Tyr of the RP1 gene. (12764676)	Fujita Y.... Saito Y.	2003	RP1
24	Insulin resistance but not hypertriglyceridemia per se is associated with endothelial dysfunction in chronic hypertriglyceridemia. (11827701)	Jonkers I.J.... Blauw G.J.	2002	INS
25	Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. (12454276)	Conde-Knape K.... Shachter N.S.	2002	LIPC, APOC1
26	Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. (11893366)	Jonkers I.J.... Smelt A.H.	2002	TNF, INS
27	Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. (11475344)	Cheng S.C.... Wu K.D.	2001	ALB, INS
28	Characterization of an apolipoprotein E3 variant (Arg 145-->His) associated with mild hypertriglyceridemia. (11337906)	Hidaka H.... Katsuyama T.	2001	LDLR, APOE
29	Two novel mutations in the lipoprotein lipase gene in a family with marked hypertriglyceridemia in heterozygous carriers. Potential interaction with the polymorphic marker D1S104 on chromosome 1q21- q23. (10787434)	Hoelzl B.... Paulweber B.	2000	LPL, IRS1, APOE
30	Tumor necrosis factor alpha as a uremic toxin: correlation with neuropathy, left ventricular hypertrophy, anemia, and hypertriglyceridemia in peritoneal dialysis patients. (10682077)	Espinoza M.... Selgas R.	1999	EPO
31	Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. (9665414)	Nauck M.S.... Marz W.	1998	APOC2
32	A novel apolipoprotein C-III variant, apoC-III(Gln38-->Lys), associated with moderate hypertriglyceridemia in a large kindred of Mexican origin. (9323592)	Pullinger C.R.... Kane J.P.	1997	APOC3
33	Risk factors for atherosclerosis in offspring of parents with primary hypertriglyceridemia (9557074)	Torbus-Lisiecka B.... CheA8stowski K.	1997	APOA1
34	Apolipoprotein E genotyping and phenotyping in type II diabetes mellitus patients with hypertriglyceridemia. (9056109)	Kim J.H.... Kwon O.H.	1997	APOE
35	Hypertriglyceridemia and plasma insulin in combined familial hyperlipidemia (9547191)	Ascaso J.F.... Carmena R.	1997	INS
36	Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. (8674885)	Ginsberg H.N.	1996	APOB
37	Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. (8531308)	Bakker-Arkema R.G.... Black D.M.	1996	HMGCR
38	Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. (8882875)	Shoulders C.C.... Cox N.J.	1996	APOC3
39	Differential effects of acute hypertriglyceridemia on insulin action and insulin receptor autophosphorylation. (8638688)	Gumbiner B.... Livingston J.N.	1996	INSR, INS
40	A tumor necrosis factor-beta polymorphism associated with hypertriglyceridemia in non-insulin-dependent diabetes mellitus. (7783649)	Vendrell J.... Richart C.	1995	TNF, LTA
41	Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. (8675619)	Weinstock P.H.... Breslow J.L.	1995	LPL
42	Hypertriglyceridemia associated with tumor necrosis factor-alpha in hamster cheek-pouch carcinogenesis. (7560416)	Nakajima J.... Harada M.	1995	LPL
43	Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. (7752906)	Sane T.... Taskinen M.R.	1995	INS
44	Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. (7578896)	Avellone G.... Bompiani G.D.	1995	PLAT, SERPINE1, APOA1
45	Hypoalphalipoproteinemia: postprandial response of subjects with preprandial normotriglyceridemia and hypertriglyceridemia to various diets. (8474323)	Edelstein C.... Scanu A.M.	1993	LPL, LIPC
46	Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. (8318063)	Simo I.E.... Ooi T.C.	1993	LPL, LIPC
47	Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. (1994722)	Reaven G.M.	1991	INS
48	Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. (1752964)	Mann C.J.... Bihain B.E.	1991	CETP
49	Apolipoprotein E allele frequencies in non-insulin-dependent diabetes mellitus with hypertriglyceridemia (type IIb, III, IV, and V hyperlipoproteinemia). (1861626)	Eto M.... Ishii K.	1991	APOE
50	Apolipoprotein E polymorphism association with lipoprotein profile in endogenous hypertriglyceridemia and familial hypercholesterolemia. (1998645)	Dallongeville J.... Lussier-Cacan S.	1991	APOE

Genes related to hypertriglyceridemia according to GeneCards:

(show top 50)    (show all 146)

id	Symbol	Description	Score	GeneCards Section Context
1	APOA5	apolipoprotein A-V	11.1	Publications, Summaries
2	APOC3	apolipoprotein C-III	11.1	Summaries, Publications
3	APOC2	apolipoprotein C-II	11.1	Publications, Summaries
4	HTGS	Hypertriglyceridemia, familial	11.1	Aliases & Descriptions
5	SLC10A2	solute carrier family 10 (sodium/bile acid cotransporter family), member 2	11.1	Summaries, Publications
6	LPL	lipoprotein lipase	11.0	Publications
7	APOE	apolipoprotein E	11.0	Publications
8	APOB	apolipoprotein B (including Ag(x) antigen)	11.0	Publications
9	APOA1	apolipoprotein A-I	11.0	Publications
10	APOA2	apolipoprotein A-II	11.0	Publications
11	LIPI	lipase, member I	11.0	Publications
12	GPD1	glycerol-3-phosphate dehydrogenase 1 (soluble)	11.0	Summaries, Publications
13	LPIN3	lipin 3	11.0	Summaries
14	LPIN2	lipin 2	11.0	Summaries
15	OA5	Osteoarthritis QTL 5	11.0
16	RP1	retinitis pigmentosa 1 (autosomal dominant)	11.0	UniProt Related, Publications
17	CETP	cholesteryl ester transfer protein, plasma	11.0	Publications
18	LIPC	lipase, hepatic	11.0	Publications
19	LPA	lipoprotein, Lp(a)	11.0	Publications
20	HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase	11.0	Publications
21	LDLR	low density lipoprotein receptor	11.0	Publications
22	SERPINE1	serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1	11.0	Publications
23	PON1	paraoxonase 1	11.0	Publications
24	ATHS	atherosclerosis susceptibility (lipoprotein associated)	11.0
25	BSCL2	Berardinelli-Seip congenital lipodystrophy 2 (seipin)	11.0
26	APOC1	apolipoprotein C-I	11.0	Publications
27	FOXC2	forkhead box C2 (MFH-1, mesenchyme forkhead 1)	11.0	Publications
28	GK	glycerol kinase	11.0	Publications
29	USF1	upstream transcription factor 1	11.0
30	CYP7A1	cytochrome P450, family 7, subfamily A, polypeptide 1	11.0	Publications
31	VLDLR	very low density lipoprotein receptor	11.0	Publications
32	FABP2	fatty acid binding protein 2, intestinal	11.0	Publications
33	RAPH1	Ras association (RalGDS/AF-6) and pleckstrin homology domains 1	11.0
34	PLA2G7	phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)	11.0	Publications
35	PNLIP	pancreatic lipase	11.0
36	COG2	component of oligomeric golgi complex 2	11.0	Publications
37	LMF1	lipase maturation factor 1	11.0	Publications
38	SCD	stearoyl-CoA desaturase (delta-9-desaturase)	11.0	Publications
39	ABCB7	ATP-binding cassette, sub-family B (MDR/TAP), member 7	11.0	Publications
40	MTTP	microsomal triglyceride transfer protein	11.0	Publications
41	LPXN	leupaxin	11.0
42	TTF2	transcription termination factor, RNA polymerase II	11.0
43	PLTP	phospholipid transfer protein	11.0
44	SMPD1	sphingomyelin phosphodiesterase 1, acid lysosomal	11.0
45	APOA4	apolipoprotein A-IV	11.0
46	G6PC	glucose-6-phosphatase, catalytic subunit	11.0
47	LTA	lymphotoxin alpha (TNF superfamily, member 1)	11.0	Publications
48	CSN1S1	casein alpha s1	11.0	Publications
49	CES1	carboxylesterase 1	11.0
50	LCAT	lecithin-cholesterol acyltransferase	11.0

Pathways related to hypertriglyceridemia according to GeneDecks:

(show all 38)

id	Pathway	Score	Top Affiliating Genes
1	Statin Pathway, Pharmacodynamics34	11.1	LPL, LIPC, LDLR, LCAT, MTTP, APOA1
2	Fat digestion and absorption20	10.9	ABCA1, AGPAT2, PNLIP, FABP2, APOB, APOA4
3	LDL-mediated lipid transport38	10.8	LDLR, LPA, CETP
4	Type II diabetes mellitus20	10.8	INS, ADIPOQ, SLC2A4, IRS1
5	Cholesterol and Sphingolipids transport / Recycling to plasma membrane in lung (normal and CF)41	10.7	APOA1, APOA2, APOA4, CAV1, ABCA1
6	Fatty acid, triacylglycerol, and ketone body metabolism38	10.7	APOA5, APOA2, ACSL5, GK, GPD1, AGPAT2
7	PPAR signaling pathway20	10.7	APOA1, APOA2, APOA5, APOC3, FABP4, FABP2
8	Cholesterol and Sphingolipids transport / Transport from Golgi and ER to the apical membrane (normal and CF)41	10.6	CES1, CAV1, ABCA1, CETP, ACAT1
9	Adipocytokines & Insulin Signaling37	10.6	IRS1, INS, RBP4, NAMPT, LEP, ADIPOQ
10	Ca, cAMP and Lipid Signaling3	10.5	APOA1, ADRB2, PDE5A, SMPD1, APOA5, APOA4
11	Insulin signaling pathway20	10.4	INSR, PHKA2, INS, G6PC, SREBF1, IRS1
12	Selected targets of HNF110	10.4	APOA1, ABCA1, NR1H4, ALB, APOB, APOA2
13	Graft-versus-host disease20	10.4	PRF1
14	AMPK Enzyme Complex Pathway36	10.2	FASN, LEP, SLC2A4, NOS3, IRS1, HMGCR
15	Blood Coagulation Signaling Pathways37	10.2	SERPINE1, F9, PLAT, KNG1, GP1BA
16	Metabolism of lipids and lipoproteins38	10.2	PPARA, GGT1, MTTP, SREBF1, CYP7B1, APOE
17	Selected targets of C/EBPalpha10	10.2	ALB, F9, FABP4, APOB, CETP, TFAP2A
18	Adipocytokine signaling pathway20	10.1	TNF, ACSL3, PPARA, IRS1, ACSL5, G6PC
19	RAR-Gamma-RXR-Alpha Degradation36	10.1	LTA, TNFSF14, OSM, BMP7
20	Glucose / Energy Metabolism3	10.1	CAT, FASN, INSR, ENPP1, SCD, PPARG
21	Caspase Cascade36	9.8	CAPN10, SMPD1, PRF1, LTA, LMNA
22	PGC1Alpha Pathway36	9.5	SLC2A4, PPARA, IL1B, IL18, BMP7, INSR
23	Metabolic pathways20	9.5	LIPC, SMPD1, PNLIP, NOS3, ACAT1, ACSL3
24	LDL Oxidation in Atherogenesis36	9.3	TNF, IL1B, VCAM1, SMPD1, ICAM1
25	PPAR Pathway36	9.1	ITGAX, ITGB2, TNF, PPARA, IL6, PPARD
26	Type I diabetes mellitus20	9.1	FAS, TNF, INS, PRF1, IL1B, LTA
27	Akt Signaling36	8.9	OSM, SLC2A4, ITGAX, TNF, IL6, IL18
28	Endothelin-1 Signaling Pathway36	8.6	IL6, OSM, BMP7, INSR, EDN1, IL18
29	Cytokine Network36	8.4	IL18, IL1B, LTA, IL6, IFNA1, TNF
30	MIF Mediated Glucocorticoid Regulation36	8.3	TNFSF14, OSM, TNF, IL6, IL1B, IL18
31	MIF Regulation of Innate Immune Cells36	8.2	TNFSF14, LTA, OSM, TNF, IL6, IL1B
32	African trypanosomiasis20	8.2	TNF, ICAM1, FAS, APOA1, IL6, IL1B
33	all-trans-Retinoic Acid Signaling in Brain36	8.2	IL6, OSM, BMP7, IL18, IL1B, TNFSF14
34	PEDF Induced Signaling36	8.1	IL18, IL6, BMP7, TNF, TNFSF14, LTA
35	Chagas disease (American trypanosomiasis)20	7.9	IL1B, TNF, IL6, C3, ACE, SERPINE1
36	Malaria20	7.9	DARC, TNF, ICAM1, IL18, IL6, IL1B
37	Tuberculosis20	7.8	IFNA1, TNF, C3, IL1B, IL6, ITGAX
38	Cytokine-cytokine receptor interaction20	7.5	LEP, TNFSF14, OSM, IFNA1, FAS, TNF

Compounds related to hypertriglyceridemia according to GeneDecks:

(show top 50)    (show all 460)

id	Compound	Score	Top Affiliating Genes
1	gemfibrozil32 9 9	13.1	COG2, LPA, LPL, LIPC, LDLR, CETP
2	bezafibrate32 9 9	13.0	COG2, SERPINE1, LPA, LPL, LIPC, LDLR
3	cholestyramine32	11.0	COG2, LPA, LDLR, CETP, CES1, APOB
4	ezetimibe32 9 9	12.9	COG2, LDLR, MTTP, CETP, CES1, INS
5	niacin32 9 9	12.8	COG2, NAMPT, LPA, LPL, LDLR, MTTP
6	phosphatidylcholine32	10.7	SELE, LPA, LPL, VCAM1, LIPC, SCD
7	cholesterol ester32	10.7	LRP1, COG2, LPA, LIPC, SCD, LDLR
8	phospholipid32	10.7	COG2, RBP4, VLDLR, LPL, LIPC, SCD
9	glucose32	10.6	BMP7, GP1BA, GPD1, PHKA2
10	palmitate32	10.5	SELE, SCD, LDLR, CETP, IRS1, APOA1
11	ritonavir32 34 9 9	13.4	LPL, LDLR, IRS1, INS, APOA1, APOA4
12	triacylglycerol32	10.4	COG2, RBP4, SERPINE1, VLDLR, LPL, LIPC
13	lovastatin32 42 9 9	13.4	LRP1, COG2, LPA, LPL, LMNA, LIPC
14	thiazolidinedione32	10.4	SERPINE1, LPL, LEP, IRS1, INS, FABP4
15	fenofibric acid32	10.4	APOC3, PPARA
16	h2o232	10.4	LPA, BCHE, LEP, LDLR, ITGB2, IRS1
17	probucol32 9 9	12.3	SELE, LPL, VCAM1, LIPC, LDLR, LCAT
18	isoproterenol32 9 9	12.2	INSR, SST, PLIN1, ADRB2, ADRB3
19	orlistat32 42 9 9	13.1	LPL, LIPC, LEP, INS, APOB, FASN
20	linoleic acid32 18	11.1	LPL, SCD, LDLR, LCAT, MTTP, CETP
21	pioglitazone32 9 9	12.0	COG2, RBP4, NAMPT, LPL, VCAM1, LIPC
22	sele32	10.0	SELP, LPL, LDLR, CETP, APOC3, APOE
23	acetyl-coa32 18	11.0	LPL, LIPC, USF1, SCD, LDLR, MLXIPL
24	oleic acid32 9 18 9	13.0	LRP1, LPA, LPL, LIPC, SCD, LDLR
25	rosuvastatin32 34 9 9	12.9	COG2, LDLR, CETP, INS, IL6, APOA1
26	sterol32	9.8	LRP1, COG2, VLDLR, LIPC, USF1, SCD
27	glutamate32	9.6	BCHE, LEP, LDLR, LCAT, ITGB2, IRS1
28	sodium nitroprusside32	9.5	IRS1, CAT, SST, PDE5A, CSN1S1, KNG1
29	aspartate32	9.5	RBP4, SELP, LDLR, CETP, ITGB2, GSR
30	uric acid32 18	10.4	GCKR, RBP4, SERPINE1, LPA, LEP, INS
31	fatty acid32	9.2	LRP1, COG2, RBP4, VLDLR, NAMPT, USF1
32	fenofibrate32 9 9	11.1	COG2, SELE, SELP, SERPINE1, LPA, LPL
33	aspirin32 34 18	10.9	COG2, SELE, SELP, SERPINE1, LPA, BCHE
34	estrogen32	8.9	COG2, RBP4, SERPINE1, LPA, LPL, BMP7
35	atorvastatin32 34 9 18 9	12.3	COG2, SELE, SELP, SERPINE1, LPA, LPL
36	8-isoprostane32	8.3	SELE, SERPINE1, VCAM1, LEP, INS, IL6
37	ibmx32	8.3	LPL, VCAM1, SCD, ITGB2, IRS1, INS
38	arginine32	8.1	COG2, LPA, LIPC, BCHE, LEP, LDLR
39	fibrinogen32	8.1	COG2, SELE, SELP, SERPINE1, NAMPT, LPA
40	rosiglitazone32 9 18 9	11.1	LRP1, COG2, RBP4, SELE, SERPINE1, NAMPT
41	arachidonic acid32 9 18 9	10.6	SELP, LPL, LIPC, BCHE, SCD, CES1
42	prostacyclin32	7.2	SELE, SELP, SERPINE1, VCAM1, LEP, LDLR
43	cholesterol32 9 18 9	10.0	LRP1, COG2, RBP4, SELE, SELP, SERPINE1
44	nitric oxide32 9 18 9	9.6	COG2, SELE, SELP, LPA, VCAM1, ITGAX
45	actinomycin d32	6.5	SELE, SERPINE1, LPA, LDLR, IRS1, INSR
46	lactate32	6.1	RBP4, SELE, SELP, LPL, VCAM1, BCHE
47	genistein32 9 18 9	9.0	SELE, SELP, SERPINE1, LPL, VCAM1, LDLR
48	lipid32	5.6	LRP1, COG2, GCKR, RBP4, SELE, SERPINE1
49	indomethacin32 9 9	7.6	LPL, LEP, LDLR, CES1, ITGAX, ITGB2
50	retinoic acid32 42 18	7.5	LRP1, RBP4, SELP, SERPINE1, VCAM1, LMNA

Cellular components related to hypertriglyceridemia according to GeneDecks:

(show all 14)

id	Name	GO ID	Score	Top Affiliating Genes
1	very-low-density lipoprotein particle	GO:034361	11.0	APOE, APOC4, APOC3, APOC2, APOC1, APOB
2	chylomicron	GO:042627	10.9	APOA5, APOE, LPL, APOA4, APOC1, APOB
3	high-density lipoprotein particle	GO:034364	10.9	LIPC, LCAT, CETP, PON1, GPIHBP1, APOE
4	low-density lipoprotein particle	GO:034362	10.8	PLA2G7, LDLR, APOC2, APOE, APOB, APOA5
5	spherical high-density lipoprotein particle	GO:034366	10.8	PON1, APOA1, APOA2, APOC2, APOC3
6	intermediate-density lipoprotein particle	GO:034363	10.8	APOC2, APOB, APOC3, APOE
7	coated pit	GO:005905	10.3	LRP1, SELE, VLDLR, LDLR, SLC2A4
8	endoplasmic reticulum lumen	GO:005788	10.3	F9, MTTP, CES1, INS, APOA1, GHRL
9	endosome lumen	GO:031904	10.1	INS, APOB, PRF1
10	caveola	GO:005901	9.7	ADRB2, CAV1, PTRF, INSR, NOS3, IRS1
11	external side of plasma membrane	GO:009897	8.6	SELP, VCAM1, LDLR, ITGAX, FAS, GPIHBP1
12	extracellular region	GO:005576	6.6	SERPINE1, APOA4, APOA5, APOB, APOC2, APOE
13	plasma membrane	GO:005886	6.5	ITGAX, TNF, TNFSF14, DARC, NOS3, PHKA2
14	extracellular space	GO:005615	5.2	IL18, TNF, TNFSF14, SST, SMPD1, PNLIP

Biological processes related to hypertriglyceridemia according to GeneDecks:

(show top 50)    (show all 101)

id	Name	GO ID	Score	Top Affiliating Genes
1	reverse cholesterol transport	GO:043691	11.1	LIPC, ABCA1, APOE, APOC3, APOC2, APOA4
2	high-density lipoprotein particle remodeling	GO:034375	11.1	CETP, LCAT, LIPC, APOA1, APOA4, APOC1
3	phospholipid efflux	GO:033700	11.1	ABCA1, APOC3, APOC2, APOC1, APOA4, APOA2
4	very-low-density lipoprotein particle remodeling	GO:034372	11.0	LCAT, LPL, LIPC, CETP, APOE, APOC2
5	chylomicron remnant clearance	GO:034382	11.0	APOE, LMF1, LIPC, APOC1, APOC2, APOC3
6	positive regulation of cholesterol esterification	GO:010873	10.9	APOA1, APOC1, APOA4, APOA2, APOE
7	low-density lipoprotein particle remodeling	GO:034374	10.9	CETP, APOA2, LIPC, PLA2G7, APOB
8	cholesterol efflux	GO:033344	10.9	APOE, APOC3, APOA2, APOC2, APOC1, APOA4
9	cholesterol homeostasis	GO:042632	10.9	ACSM3, ABCA1, CYP7A1, CAV1, GPIHBP1, ANGPTL3
10	triglyceride homeostasis	GO:070328	10.9	GPIHBP1, ANGPTL3, APOC4, APOC3, APOC2, APOA5
11	triglyceride catabolic process	GO:019433	10.9	APOA5, APOB, LIPC, APOC3, PLIN1, FABP4
12	positive regulation of lipoprotein lipase activity	GO:051006	10.9	APOC2, LMF1, APOA4, APOA5, GPIHBP1
13	Cdc42 protein signal transduction	GO:032488	10.8	ABCA1, APOC3, APOE, APOA1
14	regulation of intestinal cholesterol absorption	GO:030300	10.8	LEP, APOA4, APOA2, APOA1
15	cholesterol transport	GO:030301	10.8	APOB, APOA1, CETP, CAV1, LCAT, LDLR
16	cellular lipid metabolic process	GO:044255	10.7	APOA5, GPD1, AGPAT2, GK, PPARA, CYP7A1
17	lipoprotein metabolic process	GO:042157	10.7	APOA1, CETP, MTTP, LCAT, LDLR, LPL
18	lipid homeostasis	GO:055088	10.7	APOA4, CETP, USF1, ANGPTL3, PPARG
19	fatty acid metabolic process	GO:006631	10.7	FASN, ANGPTL3, PPARA, ACSM3, LPIN2, LPIN3
20	lipid transport	GO:006869	10.7	APOA5, GPIHBP1, PLTP, VLDLR, APOA4, CETP
21	negative regulation of macrophage derived foam cell differentiation	GO:010745	10.7	CETP, PPARA, ABCA1, ADIPOQ, PPARG
22	receptor-mediated endocytosis	GO:006898	10.7	ADRB2, VLDLR, LPA, LDLR, CETP, APOB
23	triglyceride biosynthetic process	GO:019432	10.7	AGPAT2, LPL, GPD1, LPIN2, FASN, GK
24	triglyceride metabolic process	GO:006641	10.7	LPL, CETP, APOA2, APOE, APOC3, APOC1
25	positive regulation of cholesterol efflux	GO:010875	10.6	LRP1, APOE, ABCA1, PON1, ADIPOQ
26	glucose homeostasis	GO:042593	10.6	USF1, SERPINE1, RBP4, MLXIPL, ADIPOQ, SLC2A4
27	high-density lipoprotein particle assembly	GO:034380	10.6	APOA1, ABCA1, APOE, APOA2
28	cellular response to insulin stimulus	GO:032869	10.5	SLC2A4, ACSL5, PPARG, CAPN10, ENPP1, INSR
29	cholesterol metabolic process	GO:008203	10.5	ABCA1, SREBF1, CYP7B1, CAT, APOB, LDLR
30	high-density lipoprotein particle clearance	GO:034384	10.5	APOC2, APOE, APOA1, APOA2
31	brown fat cell differentiation	GO:050873	10.4	ADRB3, FABP4, PPARG, SLC2A4, ADRB2, ADIPOQ
32	lipid metabolic process	GO:006629	10.4	APOA4, APOA2, APOA1, CETP, LCAT, LPL
33	leukocyte cell-cell adhesion	GO:007159	10.2	SELP, ITGB2, APOA4, ICAM1, SELE, VCAM1
34	response to nutrient	GO:007584	10.2	VLDLR, HMGCR, SST, PPARG, LTA, ADIPOQ
35	leukocyte tethering or rolling	GO:050901	10.1	LEP, VCAM1, TNF, SELP, SELE
36	negative regulation of lipid metabolic process	GO:045833	10.0	APOC3, IL1B, APOC1, APOC2
37	bile acid metabolic process	GO:008206	9.8	NR1H4, CYP7B1, CYP7A1, ALB, LEP, SLC10A2
38	positive regulation of lipid catabolic process	GO:050996	9.8	IL1B, APOA2, APOA5, ANGPTL3
39	glucose metabolic process	GO:006006	9.8	USF1, LEP, INPPL1, INS, GHRL, TNF
40	response to lipopolysaccharide	GO:032496	9.7	TRIB1, SELP, APOB, NR1H4, PDE5A, LTA
41	negative regulation of lipid catabolic process	GO:050995	9.6	TNF, APOC3, APOA2, IL1B, INS, BSCL2
42	response to estrogen stimulus	GO:043627	9.6	PPARG, SERPINE1, EPO, APOA2, CAV1, GHRL
43	negative regulation of MAP kinase activity	GO:043407	9.6	IL1B, APOE, HMGCR, SMPD1, ADIPOQ, GSTP1
44	response to hyperoxia	GO:055093	9.5	IL18, NOS3, EPO, CAT, SERPINE1
45	positive regulation of MAPK cascade	GO:043410	9.3	ADRB3, ADRB2, OSM, IL6, INSR, INS
46	positive regulation of nitric oxide biosynthetic process	GO:045429	8.9	INS, INSR, IL1B, ICAM1, EDN1, TNF
47	response to drug	GO:042493	8.6	FAS, ICAM1, CAV1, TNF, CYP7B1, SST
48	response to glucocorticoid stimulus	GO:051384	8.5	FAS, CAV1, TNF, PLAT, ADIPOQ, INSR
49	small molecule metabolic process	GO:044281	8.1	LPIN2, LPA, NAMPT, GCKR, LPIN3, AGPAT2
50	response to hypoxia	GO:001666	7.7	PPARA, TNF, CAT, CAV1, FAS, ADIPOQ

Molecular functions related to hypertriglyceridemia according to GeneDecks:

(show all 22)

id	Name	GO ID	Score	Top Affiliating Genes
1	phosphatidylcholine-sterol O-acyltransferase activator activity	GO:060228	10.9	APOA1, APOA2, APOA4, APOC1, APOE
2	cholesterol transporter activity	GO:017127	10.9	ABCA1, APOB, APOA4, APOA2, APOA1, CETP
3	phosphatidylcholine binding	GO:031210	10.9	CETP, APOA2, APOA5, APOC1, APOA4
4	lipid binding	GO:008289	10.8	GPIHBP1, PLIN1, PPARD, PPARA, APOE, APOC2
5	lipid transporter activity	GO:005319	10.8	CETP, APOC4, APOA4, APOA2, MTTP, APOE
6	lipase inhibitor activity	GO:055102	10.8	APOC3, APOC1, APOC2, APOA2
7	phospholipid binding	GO:005543	10.8	APOE, APOB, APOA5, APOA2, APOA1, RAPH1
8	high-density lipoprotein particle receptor binding	GO:070653	10.7	APOC3, APOA2, APOA1
9	phospholipase activity	GO:004620	10.7	LPL, LIPC, LIPH, LIPI
10	cholesterol binding	GO:015485	10.7	ABCA1, CAV1, APOC3, APOA2, APOA1, CETP
11	apolipoprotein binding	GO:034185	10.7	ABCA1, LIPC, GPIHBP1, LPA, VLDLR, LRP1
12	high-density lipoprotein particle binding	GO:008035	10.5	APOA2, GPIHBP1, APOA1
13	heparin binding	GO:008201	10.4	APOE, SELP, LPA, LIPI, LIPH, LIPC
14	sialic acid binding	GO:033691	10.2	SELE, SELP, ADIPOQ
15	fatty acid binding	GO:005504	10.1	APOC1, FABP4, FABP2, ALB, PPARD
16	enzyme binding	GO:019899	10.0	PPARG, CAV1, CAT, APOB, APOA5, BCHE
17	antioxidant activity	GO:016209	9.8	ALB, APOE, APOA4, CAT
18	protein homodimerization activity	GO:042803	9.8	ADRB2, APOA2, USF1, ADRB3, PON1, TFAP2A
19	drug binding	GO:008144	9.4	ALB, ADRB2, PPARG, ACE, PPARA, PPARD
20	receptor binding	GO:005102	9.2	ITGB2, CAT, ADIPOQ, C3, SERPINE1, LPL
21	cytokine activity	GO:005125	7.9	IL18, IL1B, BMP7, NAMPT, IL6, TNF
22	protein binding	GO:005515	5.5	APOA1, GK, CAV1, ALB, ICAM1, GP1BA